ReviewMicrobiome research reports2022
Gut microbiota signatures and modulation in irritable bowel syndrome.
Review in Microbiome research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Distinct pain profiles across irritable bowel syndrome subtypes: results from the Rome Foundation Global Epidemiology Study.Internal and emergency medicine · 2026Article
- Comparative Study on Burden, Features and Determinants of Disorders of Gut-Brain Interaction Between Southern Europe and the Rest of Continent: Results From the Rome Foundation Global Epidemiology Study.United European gastroenterology journal · 2026Article
- Deciphering the mitochondria-gut microbiota axis in irritable bowel syndrome: pathogenic insights and therapeutic frontiers.Journal of translational medicine · 2026Review
- Nutritional Management of Irritable Bowel Syndrome.Nutrients · 2026Review
- Qifuyin improves physiological frailty by regulating the intestinal flora in 3xTg-AD mice.Frontiers in microbiology · 2026Article
- Diarrhea management: from pathophysiology to microbiota modulation.Therapeutic advances in gastroenterology · 2026Review
- Review
- Functional Foods and Nutraceuticals in Irritable Bowel Syndrome.Journal of clinical medicine · 2025Review
- Impact of Microbiota on Irritable Bowel Syndrome Pathogenesis and Management: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Factors associated with symptom relief in patients with irritable bowel syndrome: a retrospective cohort study.Frontiers in medicine · 2025Article
- Functional Abdominal Bloating and Gut Microbiota: An Update.Microorganisms · 2024Review
- Insights into Probiotic Prescription among Gastroenterologists and Other Healthcare Professionals: Evidence from an Italian Survey.Journal of clinical medicine · 2024Article
- Nanovesicular Mediation of the Gut-Brain Axis by Probiotics: Insights into Irritable Bowel Syndrome.Biology · 2024Article
- Ecology- and genome-based identification of theApplied and environmental microbiology · 2024Article
- The Role of the FODMAP Diet in IBS.Nutrients · 2024Review
- An Adverse Outcome Pathway for food nanomaterial-induced intestinal barrier disruption.Frontiers in toxicology · 2024Article
- A Systematic Review: Fecal Bacterial Profile in Patients with Irritable Bowel Syndrome Analyzed with the GA-Map Dysbiosis Test Based on the 16S rRNA Gene of Bacterial Species or Groups.Clinical and experimental gastroenterology · 2024Review
- Functional Abdominal Bloating Is Associated With Gut Microbiota Dysbiosis and Altered Intestinal Barrier Function: Experimental Evidence.In vivo (Athens, Greece)Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) affects approximately one tenth of the general population and is characterized by abdominal pain associated with abnormalities in bowel habits. Visceral hypersensitivity, abnormal intestinal motor function, mucosal immune activation, and increased intestinal permeability concur to its pathophysiology. Psychological factors can influence symptom perception at the central nervous system level. In addition, recent evidence suggests that dysbiosis may be a key pathophysiological factor in patients with IBS. Increasing understanding of the pathophysiological mechanisms translates into new and more effective therapeutic approaches. Indeed, in line with this evidence, IBS therapies nowadays include agents able to modulate gut microbiota function and composition, such as diet, prebiotics, probiotics, and antibiotics. In addition, in the last decade, an increasing interest in fecal microbiota transplantation has been paid. An in-depth understanding of the intestinal microenvironment through accurate faucal microbiota and metabolite analysis may provide valuable insights into the pathophysiology of IBS, finally shaping new tailored IBS therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.